Harmony Biosciences Holdings (HRMY) Income from Continuing Operations (2019 - 2026)

Harmony Biosciences Holdings has disclosed Income from Continuing Operations across 8 years of filings, most recently posting 32488000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 32488000.0, down 28.69% year-over-year; the trailing twelve-month figure through Mar 2026 was 160243000.0 (down 12.04% YoY), and the FY2025 annual result was 173315000.0, down 0.94% from the prior year.
• Income from Continuing Operations came in at 32488000.0 for Q1 2026 at Harmony Biosciences Holdings, down from 37114000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 87943000.0 in Q3 2022 to a low of 37434000.0 in Q4 2022.
• The 5-year median for Income from Continuing Operations is 37114000.0 (2025), against an average of 35596411.76.
• Peak annual rise in Income from Continuing Operations reached 1014.17% in 2022, while the deepest fall reached 296.42% in 2022.
• Harmony Biosciences Holdings' Income from Continuing Operations stood at 37434000.0 in 2022, then jumped by 171.08% to 26607000.0 in 2023, then surged by 196.69% to 78940000.0 in 2024, then sank by 52.98% to 37114000.0 in 2025, then fell by 12.46% to 32488000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 32488000.0 (Q1 2026), 37114000.0 (Q4 2025), and 50865000.0 (Q3 2025), per Business Quant data.